Pediatrix Medical Group, Inc. (NYSE:MD) Receives Average Rating of "Hold" from Brokerages

Shares of Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) have been given an average recommendation of "Hold" by the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $16.10.

MD has been the subject of several recent research reports. Truist Financial lifted their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a "hold" rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft lifted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a "hold" rating in a report on Monday, November 4th. UBS Group lifted their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. StockNews.com raised Pediatrix Medical Group from a "sell" rating to a "hold" rating in a report on Wednesday, August 7th. Finally, Jefferies Financial Group lifted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th.

Insider Activity at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the business's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares of the company's stock, valued at approximately $343,783.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO James D. Swift sold 11,100 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of the company's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares of the company's stock, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Rubric Capital Management LP boosted its stake in Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company's stock valued at $61,532,000 after buying an additional 7,241,400 shares during the last quarter. Dana Investment Advisors Inc. boosted its stake in Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company's stock valued at $7,725,000 after buying an additional 455,785 shares during the last quarter. Boston Partners boosted its stake in Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company's stock valued at $17,702,000 after buying an additional 453,254 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company's stock valued at $2,192,000 after buying an additional 251,072 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new position in Pediatrix Medical Group during the second quarter valued at approximately $1,721,000. Hedge funds and other institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Stock Up 1.2 %

Shares of MD traded up $0.19 during trading hours on Monday, reaching $15.95. The stock had a trading volume of 220,138 shares, compared to its average volume of 869,504. Pediatrix Medical Group has a 12 month low of $6.62 and a 12 month high of $16.41. The firm has a 50-day simple moving average of $12.08 and a 200 day simple moving average of $9.64. The company has a current ratio of 1.42, a quick ratio of 1.38 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -5.15, a P/E/G ratio of 2.26 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. During the same period in the prior year, the firm posted $0.29 EPS. Pediatrix Medical Group's quarterly revenue was up .9% compared to the same quarter last year. Equities research analysts predict that Pediatrix Medical Group will post 1.25 earnings per share for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.